Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

487.000
+14.0002.96%
Volume:852.60K
Turnover:415.18M
Market Cap:116.39B
PE:-293.93
High:497.800
Open:465.200
Low:465.200
Close:473.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:2.11
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.67
PE(LYR):-293.93
PS:47.77

Loading ...

SKB BIO commits RMB 400.00 million to third BOC structured deposit, lifting total holdings to RMB 1.10 billion

Bulletin Express
·
Aug 04

SKB BIO Invests 400 Million Yuan in Bank of China Structured Deposits

Stock News
·
Aug 04

Sichuan Kelun-Biotech Biopharmaceutical Subscribes to BOC Structured Deposit III for Rmb400 MLN

Reuters
·
Aug 04

Sichuan Kelun-Biotech Biopharmaceutical Co - Subscribes to BOC Structured Deposit Iii for Rmb400 Mln on August 4, 2026

THOMSON REUTERS
·
Aug 04

Movement Alert|SKB BIO Declines 3.35% in Regular Trading, Commercial Bribery Allegations Continue to Weigh on Shares as Strict New Pharma Regulations Take Effect

Market Focus
·
Aug 03

Sichuan Kelun Biotech (SEHK:6990) Wins Priority Review For Sixth Sac TMT Indication

Simply Wall St.
·
Aug 01

Movement Alert|SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA

Market Focus
·
Jul 31

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 30

Kelun-Biotech (SKB BIO): NMPA Accepts Sixth Indication Filing for TROP2 ADC sac-TMT as First-Line Therapy in PD-L1-Low TNBC

Bulletin Express
·
Jul 30

Kelun-Biotech Says China Regulator Accepts sac-TMT Filing for First-line Metastatic TNBC Use

Reuters
·
Jul 30

Sichuan Kelun-Biotech Biopharmaceutical Co - Nmpa Accepts New Indication Application for Sac-TMT in First-Line Tnbc

THOMSON REUTERS
·
Jul 30

Movement Alert|SKB BIO Declines 3.01% in Regular Trading, Trading at 482.6 HKD

Market Focus
·
Jul 30

MerckRapidly Advances ADC+IO 2.0 Strategy with SKB BIO's TROP2 ADC Joint PD-1/VEGF Bispecific Antibody Phase II Trial

Deep News
·
Jul 29

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA IND Approval for Skb565

Reuters
·
Jul 27

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-Payload ADC Skb565

THOMSON REUTERS
·
Jul 27

SKB BIO Receives NMPA Approval for Clinical Trial of Novel Dual-Load ADC Drug

Stock News
·
Jul 27

Kelun-Biotech Wins China IND Clearance for Skb565 in Advanced Solid Tumors

Reuters
·
Jul 27

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives Nmpa Ind Approval for Skb565 for Advanced Solid Tumors

THOMSON REUTERS
·
Jul 27

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.62% at Open, Investment Banks Raise Target Prices Amid Institutional Accumulation Wave

Market Focus
·
Jul 22